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Abstract
Botulinum neurotoxins (BoNTs) are among the most lethal biological substances to have been weaponized and are listed as
biodefense category A agents. Currently, no small molecule (non-peptidic) therapeutics exist to counter this threat; hence, identifying and developing compounds that inhibit BoNTs is a high priority. In the present study, a high-throughput assay was used to
identify small molecules that inhibit the metalloprotease activity of BoNT serotype A light chain (BoNT/A LC). All inhibitors were
further veriﬁed using a HPLC-based assay. Conformational analyses of these compounds, in conjunction with molecular docking
studies, were used to predict structural features that contribute to inhibitor binding and potency. Based on these results, a common
pharmacophore for BoNT/A LC inhibitors is proposed. This is the ﬁrst study to report small molecules (non-peptidics) that inhibit
BoNT/A LC metalloprotease activity in the low lM range.
Ó 2003 Elsevier Inc. All rights reserved.
Keywords: Bioterrorism; Botulinum neurotoxin; Drug discovery; High-throughput screen; Inhibitors; Molecular modeling; Pharmacophore; Threedimensional database search; Metalloprotease

Botulinum neurotoxins (BoNTs) are produced by
spore forming anaerobic bacteria Clostridium botulinum
and are among the most lethal of biological poisons
[1,2]. Seven immunologically distinct BoNT serotypes
(designated A-G) have been identiﬁed [3]. Accidental
exposure to BoNTs, for example through contaminated
food, can result in life threatening ﬂaccid paralysis [4].
Furthermore, BoNTs have been weaponized in highly
toxic aerosol form, and consequently pose a signiﬁcant
“dual threat”—i.e., both to civilian and military populations [5,6]. As a result, there is an urgent need for
therapeutic countermeasures against BoNTs [7].
*
Corresponding authors. Fax: 1-301-846-6106 (R. Gussio), Fax:
1-301-619-2348 (S. Bavari).
E-mail addresses: Gussio@NCIFCRF.GOV (R. Gussio), Sina.
Bavari@AMEDD.ARMY.MIL (S. Bavari).

BoNT is secreted as a holotoxin composed of two
peptide chains that are linked by a disulﬁde bridge [8].
The heavy chain is responsible for: (1) targeting and
binding to surface receptors on nerve terminals; (2)
translocation into the neuronal cytosol via the formation of a low pH endosome; and (3) protecting the
substrate binding cleft of the light chain prior to neuronal internalization [9,10]. The light chain, which dissociates from the heavy chain in the low endosomal pH,
is released into the cytosol where it acts as a zinc metalloprotease that cleaves SNARE (soluble NSF-attachment protein receptor) proteins: SNAP-25
(synaptosomal-associated protein of 25 kDa), synaptobrevin, and syntaxin [9,10]. BoNT serotypes A, C,
and E cleave SNAP-25 [11]; serotypes B, D, F, and G
cleave synaptobrevin [12–15]; and serotype C can also
use syntaxin as substrate [16]. Without functional
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SNARE complexes, acetylcholine is not released into
neuromuscular junctions, leading to paralysis.
Research to identify peptide and small molecule inhibitors of BoNT serotype A (BoNT/A) has targeted
both holotoxin translocation and light chain (BoNT/A
LC) metalloprotease activity. Sheridan et al. [17] and
Deshpande et al. [18] have shown that a number of antimalarial agents interfere with BoNT/A translocation
into nerve cytoplasm. Speciﬁcally, it has been shown that
several antimalarial compounds act subsequent to toxin
binding to cell-surface receptors [17], and it has been
hypothesized that these agents inhibit BoNT/A cytosol
entry by raising endosomal pH (an endosomal pH of 5.5
or lower is needed for release into the cytoplasm) [17,18].
Hayden et al. [19] have found that BoNT/A LC is inhibited by mM concentrations of known protease inhibitors: captopril, lysinopril, and enalapril. In the same
study, it was also reported that a number of short peptides, from speciﬁc “hinge” libraries, inhibit BoNT/A LC
activity by as much as 51% at concentrations as low as
0.5 lM [19]. Using a chromatographic method, Schmidt
et al. [20] identiﬁed the peptide motif CRATKML as a
potent inhibitor. In a subsequent study, the Cys residue
of CRATKML was replaced with thiol containing
organic moieties and it was found that a 2-mercapto3-phenylpropionyl containing derivative was the most
eﬀective (Ki ¼ 0:3 lM) [21].
Presently, no small molecule (non-peptidic) inhibitors
of BoNT/A LC metalloprotease activity, which are effective in the low lM range, have been reported. In this
report, a high-throughput assay was used to facilitate
BoNT/A LC inhibitor identiﬁcation [22]. Initially, the
National Cancer Institute (NCI) Diversity set was
screened, and several compounds possessing >50% inhibition (at 20 lM concentration) were identiﬁed. Based
on molecular modeling studies, common structural
features and binding modes in the BoNT/A LC substrate binding cleft were identiﬁed for these leads. Additional screening of 7-chloro-4-aminoquinoline
derivatives also resulted in the identiﬁcation of leads
that substantially inhibit BoNT/A LC at 20 lM concentrations. Analyses of these compounds indicate that
they share common structural/functional group characteristics with inhibitors identiﬁed during the screen of
the NCI Diversity set, and that they may also bind to
the enzyme’s substrate binding cleft in a similar manner.
Based on our analyses, a common pharmacophore for
BoNT/A LC inhibitors is proposed.
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described previously [23,24]. Amodiaquine, chloroquine, quinacrine,
quinidine, and quinine were obtained from Sigma–Aldrich (USA).
High-throughput assay of BoNT/A LC activity. The high-throughput assay used to screen BoNT/A LC proteolytic activity has been
described previously [22]. Brieﬂy, liquid transfers were done with a
SciClone automated pipettor (Zymark, Hopkinton, MA). Recombinant BoNT/A LC [25] was diluted to 0.6 lg/ml in 40 mM Hepes,
and 0.5 mg/ml BSA, pH 7.4. Test compounds was diluted to 0.2 mM
with methyl sulfoxide. Ten microliters of each compound were transferred into the corresponding wells of another 96-well plate containing
immobilized ﬂuorescent-labeled peptide substrate, speciﬁc for the
protease activity of BoNT/A LC [22]. Ninety microliters BoNT/A LC
was then added and mixed, for ﬁnal concentrations of 20 lM compound and 0.5 lg/ml BoNT/A LC. Blanks (buﬀer only) and controls
(buﬀer and BoNT/A LC), eight wells each, were included on each assay
plate. After incubation at 30 °C for 60 min, 70 ll was transferred from
each well to an opaque-wall plate and ﬂuorescence was measured in a
Wallac 1420 multi-label counter (Perkin–Elmer, Gaithersburg, MD).
HPLC-based assay of BoNT/A LC protease activity. Compounds
exhibiting P 40% inhibition in high-throughput assays were retested
in a HPLC-based assay as described previously [1,26].
BoNT/A LC reﬁnement and inhibitor docking. The structure of
BoNT/A LC was obtained from the deposited crystallographic coor holodinates of the holotoxin (PDB refcode ¼ 3BTA) [27]. The 3.2 A
toxin includes the heavy chain, light chain, and a protective residue
belt that covers the substrate binding site of the light chain. The heavy
chain and the protective belt were removed from the holotoxin, and the
light chain was energy reﬁned using the Discover (Accelrys, San Diego,
CA) program’s cﬀ91 force ﬁeld. During the reﬁnement, the zinc ion
and residues coordinating the zinc ion were ﬁxed in their original co2 of force
ordinates. Our strategy entailed applying 2000 kcal/mol per A
that was stepped oﬀ the structure in 100-kcal/mol decrements by
minimizing with conjugate gradients, until the norm of the gradient
 [28]. This process was repeated until all applied exwas 0.01 kcal/A
ternal force was removed. The resulting coordinates of the ﬁnal model
were within the experimentally determined X-ray crystallographic

resolution. The optimized structure had an rms deviation of 2.6 A
across all backbone atoms from the reported crystallographic coordinates of the holotoxin light chain.
Using InsightII molecular modeling software (Accelrys, San Diego,
CA), identiﬁed inhibitors were manually docked into the BoNT/A LC
 were
substrate binding cleft, and van der Waals violations of 0.25 A
removed by small adjustments to side-chain torsion angles and inhibitor positioning. The inhibitor-enzyme structure coordinates were
subsequently tether minimized in the same manner as described above
and the ﬁnal structure was subjected to hydropathic analysis using the
program HINT (eduSoft, Richmond, VA).
Conformer generation. Conformational models of inhibitors were
generated using Catalyst 4.7 software (Accelrys, San Diego, CA). Inhibitors were imported into Catalyst and energy minimized to the
closest local minimum using the generalized CHARMM-like force
ﬁeld, as implemented in the program. Following, the “best quality”
conformational search option was employed to generate conformers
within 20 kcal/mol from the global energy minimum. In this study, it
was found that 100 conformers per compound ensured adequate
coverage of conformational space.

Results and discussion
Materials and methods
Screening of the NCI diversity set
Compounds. The NCI Diversity set was obtained in 96-well plate
format from the National Cancer Institute (http://dtp.nci.nih.gov/
branches/dscb/diversity_explanation.html). The syntheses of N,
N-bis(7-chloroquinolin-4-yl)alkanediamines and N,N-bis(7-chloroquinolin-4-yl)heteroalkanediamines used in these studies have been

A high-throughput ﬂuorescence-based assay was initially used to screen the NCI diversity set: a collection of
1990 molecules that were selected to cover a wide range
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of conformational space, and at the same time provide
pharmacophore diversity and structural rigidity. Following the initial high-throughput screen, a HPLCbased assay [1,26] was used to eliminate false positives
resulting from ﬂuorescence quenching by some of the
compounds. The ﬁnal set of inhibitors, which were tested at 20 lM concentration in the presence 0.1 mM
substrate, consisted of 21 compounds with potencies
ranging from 14% to 100% BoNT/A LC inhibition.
Two-dimensional structures for compounds possessing
>40% inhibition are shown in Table 1.

Additional testing of NSC 625324 (silver sulfadiazine), initially the most potent of the identiﬁed compounds, indicated that this molecule’s eﬃcacy was
entirely mediated by the silver ion: no inhibition was
observed when the unionized, organic form of sulfadiazine was tested in the HPLC-based assay. Furthermore,
BoNT/A LC activity was examined in the presence of
silver acetate, and 100% inhibition of protease activity
was found at concentrations P5 lM silver ion (the IC50
was 1.5–2.0 lM). Cesium and rubidium salts did not
inhibit BoNT/A LC protease activity at concentrations

Table 1
NCI diversity set inhibitors of BoNT/A LC
Compound

a

NSC No.

% Inhibitiona

NSC 625324 (silver sulfadiazine)

100

NSC 661755 (michellamine B)

62

NSC 357756

57

NSC 119889

56

NSC 86372

51

NSC 130796

48

NSC 402959

40

Compounds tested in the HPLC-based assay at 20 lM concentration in the presence of 0.1 mM substrate.
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up to 20 lM. The presence of zinc (5–50 lM) in assays
had no eﬀect on inhibition by 3 lM silver ion, but addition of 1 mM DTT immediately reversed inhibition.
These observations suggest that silver neither displaces
zinc from the active site, nor causes irreversible denaturation by reacting with a residue important for conformational stability. It is possible that this ion might
bind to polar residues in or near the substrate binding
cleft, blocking access to the catalytic site.
Inhibitors NSC 86372 and 130796 both contain an 8hydroxyquinoline moiety (Table 1), which is known to
chelate metal ions [29]. Based on our analyses, both of
these molecules do chelate the BoNT/A LC catalytic
zinc. Support for a chelation mechanism is based on: (1)
assay data showing that several congeners of NSC 86372
possess equivalent inhibitory potency to that of the
original lead molecule; (2) addition of 20 lM zinc immediately and quantitatively reversed inhibition caused
by up to 10 lM NSC 86372; and (3) NSC 86372, its
congeners, and NSC 130796 inhibit other zinc metalloproteases (including anthrax lethal factor and BoNT
serotype B light chain (BoNT/B LC)). Consequently, the
8-hydroxyquinoline motif is not suitable for further
development as a component of BoNT/A LC inhibitors;
however, as will be shown, structural similarities between NSC 86372 and other identiﬁed compounds do
appear to ﬁt a general model for BoNT/A LC inhibition.
Screening of 7-chloro-4-aminoquinoline derivatives
Congeneric series of N,N-bis(7-chloroquinolin-4yl)alkanediamines [23] and N,N-bis(7-chloroquinolin-4yl)heteroalkanediamines [24] (collectively referred to as
BQs for the remainder of the text) were examined for
BoNT/A LC inhibition. The compounds were tested in
the HPLC-based assay at 20 lM concentration in the
presence of 0.1 mM substrate [1,26]. Inhibition of
BoNT/A LC by these compounds was not aﬀected by
added zinc. Furthermore, when tested against BoNT/B
LC protease activity, no signiﬁcant inhibition was
found. Taken together, these observations suggest that
these compounds exhibit speciﬁcity for binding to
BoNT/A LC and are not zinc chelators. Table 2 shows
the two-dimensional structures of these compounds,
along with percent inhibition of BoNT/A LC.
Results from our studies on BQs led us to hypothesize
that other quinoline-based compounds might also inhibit BoNT/A LC enzymatic activity. One method for
fast tracking the evolution of therapeutics against
BoNT/A LC would be to identify inhibitors of this enzyme that are already approved drugs (and subsequently
already possess pharmacological and toxicological data
from clinical trials). Subsequently, we tested ﬁve readily
available antimalarial drugs—amodiaquine, chloroquine, quinacrine, quinidine, and quinine—that share
similar structural characteristics with the BQs. These
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compounds were obtained and examined in our HPLCbased assay; structures of these compounds and percent
inhibition of BoNT/A LC protease activity are shown in
Table 2.
Identiﬁcation of structural similarities and potential
binding sites for inhibitors from the NCI diversity set
Superimpositions of several of the most potent inhibitors identiﬁed during the NCI Diversity set screen
are shown in Fig. 1. An evident feature to emerge from
superimposing these compounds is that they all possess
biaryl and triaryl heterocyclic scaﬀolds (for example,
quinoline, phenazinium, or xanthene). The exception to
this observation is michellamine B—the central naphthalenes of this molecule do not possess heteroatoms.
However, like aromatic heterocyclic nitrogens or oxygens, hydroxy and methoxy substituents on the naphthalene rings may participate in electron donating
interactions. The superimposed structures in Fig. 1 also
indicate that possessing hydrophobic moieties at either
end of the aromatic components may be important for
potency.
To gain a better understanding of how these inhibitors interact with BoNT/A LC, molecular docking
studies were performed. Michellamine B (Table 1) was
the ﬁrst inhibitor to be examined. This molecule was the
best lead for initially probing the steric constraints of the
substrate binding cleft, as it is an atropisomer that results from hindered rotation of about single bonds [30–
33]; it possesses restricted conformations, which reduces
the number of potential binding modes that it may assume in the enzyme’s substrate binding cleft. Furthermore, unlike NSC 86372, inhibition of BoNT/A LC by
michellamine B is not aﬀected by added zinc, suggesting
that inhibition is not simply the result of michellamine B
acting as a chelator.
Fig. 2 shows michellamine B docked in the BoNT/A
LC substrate binding cleft. There is a good complement
between the steric space of the binding cleft and the twist
planar conformation of michellamine B. Hydropathic
analyses of favorable and unfavorable contacts in several docked models indicated that the best binding mode
results when the naphthalenes (labeled A and B for descriptive purposes, Fig. 2) extend down the length of the
catalytic cleft. In this model, the two hydroxyl moieties
of the naphthalenes exist in close proximity to the catalytic zinc and form an intramolecular hydrogen bond.
Either of the hydroxyl moieties may displace the water
molecule that is used by the enzyme’s catalytic engine
during peptide lysis. As seen in Fig. 2, the methoxy and
methyl groups of naphthalene A point toward a hydrophobic pocket (referred to as binding subsite 1 for
the remainder of the text) that is formed by the aromatic
side-chains of residues Phe 162, Phe 177, and Phe 193, as
well as the side-chain methyl of Thr 219. The methoxy
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Table 2
Quinoline-based inhibitors of BoNT/A LC
Bisquinolines (BQs)

Compound

% Inhibitiona

Q1-21

24

Q3-87

7

Q2-59

26

Compound
Q3-81

% Inhibitiona
32

27
Q3-79

Q1-19

5

Q2-61

50

15
Q2-97

Q2-15

60

Q2-43

52

8
Q2-11

Q1-3

12

Antimalarial drugsb

a
b

20

30

30

9
3

Compounds tested in the HPLC-based assay at 20 lM concentration in the presence of 0.1 mM substrate.
Antimalarial drugs tested in the HPLC-based assay to 50 lM concentration in the presence of 0.2 mM substrate.

moiety of naphthalene B packs into a deep pocket (referred to as binding subsite 2 for the remainder of the
text) that is located behind His 226 of the catalytic engine, and surrounded by residues Met 164, Thr 175, Arg
230, and Pro 238. The methyl moiety of naphthalene B
packs into space behind the side-chain pyrrolidine of
Pro 238.

The tetrahydroisoquinoline attached to naphthalene
A binds in such a way that the 6,8-diol moieties point
toward the solvent, while the 1,3-dimethyl moieties
point toward hydrophobic residues of the substrate
binding cleft. The ionizable amine of the tetrahydroisoquinoline attached to naphthalene B points towards a
cluster of polar residues, including Glu 55, Gln 161, Glu

J.C. Burnett et al. / Biochemical and Biophysical Research Communications 310 (2003) 84–93

Fig. 1. Overlay of BoNT/A LC inhibitors from the NCI Diversity set.
For all structures, nitrogen atoms are blue, oxygen atoms are red, and
iodine atoms are orange. Carbon atoms for michellamine B are green,
for NSC 86372 are light blue, for NSC 357756 are magenta, and for
NSC 119889 are white. There are structural trends in: (1) the superimposed aromatic scaﬀolds and (2) the positioning of hydrophobic
moieties.
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Subsequent docking studies with other BoNT/A LC
inhibitors from the NCI Diversity set indicated that
these compounds may use binding modes similar to that
of michellamine B. Fig. 3 shows a two-dimensional
schematic that matches inhibitor substituents with proposed binding subsites for three inhibitors from the NCI
Diversity set. Our analyses indicate that the most potent
inhibitors engage in contacts with residues in both
binding subsites 1 and 2, and in each case, either an
oxygen or a nitrogen (in an aromatic heterocyclic ring) is
positioned in close proximity to the catalytic zinc. For
example, the 8-hydroxyquinoline of NSC 86372 (Fig. 3),
when optimized in the substrate binding cleft, is positioned in such a way that zinc chelation is possible.
Additionally, the methyl substituent of the compound’s
quinolinium substituent inserts into binding subsite 2
(similar to the methoxy moiety of michellamine B
naphthalene B), while the ethoxy moiety of the quinolinium ﬁlls space located behind Pro 238 (similar to the
methyl moiety of michellamine B naphthalene B).
In another example, the most favorable binding mode
of NSC 357756 indicates that the dihydro-imidazolyl
(attached to the benzofuran) inserts into binding subsite
1 (Fig. 3) (the same pocket that is occupied by the
methoxy and methyl moieties of michellamine B naphthalene A (Fig. 2)). The oxygen of the benzofuran
moiety is positioned in close proximity to the zinc ion,
and the 3-amino substituent on the indole ring engages
in a hydrogen bond with Glu 163. In binding subsite 2, a
nitrogen in the dihydro-imidazolyl (which is attached to
the 6 position of the indole) engages in a hydrogen bond

Fig. 2. Michellamine B docked in the BoNT/A LC substrate binding
cleft. Nitrogen atoms are blue and oxygen atoms are red. Carbon atoms of michellamine B are white, and the naphthalene scaﬀolds of the
inhibitor are labeled A and B (as referenced in the text). Carbon atoms
of residues in predicted binding subsites are light blue (binding subsite
1 in the text), light green (binding subsite 2 in text), and magenta
(referred to as the polar region in the text). All other enzyme carbons
are green. For michellamine B, the methoxy and methyl substituents of
naphthalene A pack into binding subsite 1, while the methoxy
of naphthalene B packs into binding subsite 2. The ionizable nitrogen
of the tetrahydroisoquinoline attached to naphthalene B points toward
a cluster of polar residues: Glu 55, Gln 161, Glu 163, and Lys 165.

163, Lys 165, and Arg 176, and may either engage directly in an ionic bond with one of the Glu residues in
this area, or participate in a water mediated hydrogen
bond with any of the indicated polar residues (Fig. 2).
Along the same lines, the ionizable amine may also serve
to solubilize the tetrahydroisoquinoline ring. The 6,8diol substituents of this tetrahydroisoquinoline are oriented toward the solvent interface.

Fig. 3. A two-dimensional schematic relating compound substituents
to predicted binding subsites in the BoNT/A LC substrate binding
cleft. Dashed circles indicate substituents that engage in favorable
contacts in binding subsite 1, solid circles indicate substituents that
engage in favorable contacts in binding subsite 2, and gray spheres
indicate substituents that engage in favorable interactions with polar
residues.
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with the side-chain guanidinium of Arg 230, while the
methylenes of this ring pack behind the pyrrolidine ring
of Pro 238.
Structural evaluation and molecular docking of BQs and
antimalarial drugs
BQs possessing a ﬂexible linker between the 7-chloro4-aminoquinoline moieties are more potent inhibitors
than conformationally constrained derivatives (Table 2).
In addition, it is also evident that an ionizable amine in
the ﬂexible linker increases potency (for example, Q2-61
versus Q1-19). Compound Q2-15 shows that a seven
atom linker, with a central ionizable amine, is favored
over shorter linkers that also contain an ionizable amine.
Conformational analyses of the most potent BQs
show that these compounds favor a folded conformation, with the 7-chloro-4-aminoquinoline moieties positioned front to back and slightly oﬀset relative to one
another (Fig. 4A). Based on these observations, it appears that these congeners may all bind in the BoNT/A
substrate binding cleft in a similar manner.
To gain a better understanding of how the folded
conformations of these congeners might bind in the
BoNT/A LC substrate cleft, Q2-15 was ﬁt onto michellamine B (in its docked conformation). The superimposition shown in Fig. 4B indicates a good overlap
between: (1) the 7-chloro-4-aminoquinoline components
of Q2-15 and the naphthalene moieties of michellamine
B and (2) the ionizable nitrogen of the Q2-15 ﬂexible
linker and the ionizable nitrogen of one of the michellamine B isoquinolines.
These observations led to docking studies to determine if the BQs might also bind to predicted subsites 1
and 2 in the BoNT/A LC substrate binding cleft. For the
most potent compounds, the ring nitrogen of one of the
7-chloro-4-aminoquinoline moieties sits in close proximity to the catalytic zinc, while the 7-chloro substituent
packs into binding subsite 1. The ionizable amines in
compounds with ﬂexible linkers engage in potential ionic bonds with the polar side-chains of either Gln 161 or
Glu 163. Another explanation for the importance of the
ionizable amine may be that it is necessary for solubilizing the otherwise hydrophobic linkers found in this
series of compounds.
Docking studies also indicate that the second 7chloro-4-aminoquinoline moiety (of the most potent
derivatives) binds in subsite 2 such that the nitrogen of
the heterocycle points toward the solvent and engages in
a hydrogen bond with the side-chain guanidinium of
Arg 230 (as was also observed for a nitrogen in one of
the dihydro-imidazolyl rings of NSC 357756), and the 7chloro substituent points into the hydrophobic space
behind His 226. For comparison, molecular docking of
compounds with rigid linkers (for example, Q2-11 and
Q2-97) indicates that steric constraints prevent these

compounds from adopting binding modes in subsites 1
and 2 that are as favorable as those observed for
congeners with ﬂexible linkers. In general, these studies
provide evidence that the BQs interact with the BoNT/A
LC substrate binding cleft in a manner similar to inhibitors from the NCI Diversity set. Fig. 3 shows twodimensional schematics matching substituents from two
of the most potent BQs (Q2-15 and Q3-81) with their
corresponding binding subsites in the BoNT/A LC
substrate binding cleft.
Of the ﬁve examined antimalarial drugs (Table 2),
amodiaquine and quinacrine were the most potent (30%
inhibition of protease activity). However, the fact that
these two drugs inhibit BoNT/A LC with approximately
half the potency of Q2-15 provides further evidence that
a second aromatic component, such as found in the BQs
or michellamine B, is necessary for enhanced potency,
and supports our hypothesis that binding subsite 2 (in
the enzyme’s substrate binding cleft) is an important
contact region for inhibitors. Furthermore, as quinacrine contains an acridine scaﬀold, these studies have
revealed a new aromatic component that may be used to
identify and/or synthesize new BoNT/A LC inhibitors.
The antimalarial agents that we found to inhibit
BoNT/A LC protease activity have previously been
shown to increase the time to BoNT/A holotoxin induced muscle paralysis [17,18]. In the earlier work, it
was hypothesized that these compounds delayed paralysis by interfering with toxin translocation into the
nerve cytoplasm and therefore they were not tested for
speciﬁc inhibition of BoNT/A LC protease activity. The
percent inhibition of BoNT/A LC that we observed for
these drugs was not equivalent to the level of protection
that they aﬀorded against muscle paralysis in the previous studies [17,18]. For example, quinacrine, which we
report to inhibit BoNT/A LC protease activity by 30%
at 50 lM (0.2 mM substrate), was found, in an earlier
study [17], to delay the time to 50% muscle paralysis by
at least 30% (over control) at 3.3 lM [17]. Thus, the
results from the earlier studies, combined with the
ﬁndings from our investigation, suggest that these
compounds possess a dual mechanism of action—interfering with both BoNT/A entry into the cytoplasm and
with the protease activity of the light chain. This dual
mechanism of action is appealing from a drug design
standpoint, as one molecule can be used to inhibit two
separate functions of the same target. Indeed, if the BQs
are found to also inhibit BoNT/A cytoplasm entry, then
these studies will be the basis for the development of a
new family of bifunctional inhibitors.
A common pharmacophore for BoNT/A LC inhibitors
Based on conformational sampling and molecular
docking studies, a common pharmacophore for BoNT/
A LC inhibitors is proposed (Fig. 5A). An example of
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Fig. 4. (A) Overlay of folded conformers of BQs: Q1-21, Q2-15, Q3-79,
and Q3-81. For all compounds, nitrogen atoms are dark blue and
chlorine atoms are light green. The carbon atoms of Q1-21 are magenta, of Q2-15 are light blue, of Q3-79 are green, and of Q3-81 are
white. A striking feature of the superimposed compounds is the close
correspondence of their chloro substituents, which provides evidence
that they may bind within the enzyme’s substrate binding cleft in a
similar manner. (B) Overlay of michellamine B and Q2-15. Carbons of
michellamine B are green and carbon atoms of Q2-15 are light blue.
The superimposed conformers show a good correspondence between:
(1) the ionizable amine in the ﬂexible linker of Q2-15 and the ionizable
amine in one of the tetrahydroisoquinolines of michellamine B and (2)
the chloro moieties of Q2-15 and the hydrophobic methoxy/methyl
moieties of michellamine B.

how one of the inhibitors (Q2-15) ﬁts the pharmacophore, using Catalyst 4.7 (Accelrys, San Diego, CA) as
the query engine, is shown in Fig. 5B. Speciﬁcally, our
studies show that the BoNT/A LC binding cleft can
accommodate up to two biaryl/triaryl aromatic components, which are deﬁned by planes A and B in the
pharmacophore (Fig. 5A). These planes serve as scaffolds for positioning other components of the pharmacophore, provided that the distance between centroids of

the two planes only varies from approximately 6.5–9.5 A
(Fig. 5A). An additional requirement of plane A is the
presence of a heteroatom (Fig. 5A) that may serve to
either directly engage in an interaction with the catalytic
zinc, or potentially replace the water molecule used by
zinc during substrate lysis. Examples of structural
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Fig. 5. (A) Common pharmacophore for BoNT/A LC inhibition.
Planar components A and B are blue dashed rectangles. The dashed
green circle in plane A represents a heteroatom. Hydrophobic components of the pharmacophore (C and D) are shown with light blue
spheres. The positive ionizable component of the pharmacophore (E) is
shown with a red sphere. (B) Q2-15 mapped onto the common pharmacophore (shown in (A)) in Catalyst 4.7 (Accelrys, San Diego, CA).
Carbon atoms are black, nitrogen atoms are blue, and chlorine atoms
are green. Planar components A and B are outlined with blue dashed
rectangles. The heteroatom in plane A is indicated with a dashed green
circle. Mapping of the hydrophobic components (C and D) is indicated
with light blue mesh spheres; mapping of the positive ionizable component (E) is indicated with a red mesh sphere.

components of inhibitors that occupy planes A and B
include: the two quinoline rings of BQs (a quinoline
nitrogen would be the electron donor) (Table 2, Figs. 3,
4, and 5B); the two naphthalene rings of michellamine B
(a hydroxyl oxygen would be the electron donor) (Table
1, Figs. 2 and 3); and the indole and benzofuran rings of
NSC 357756 (the benzofuran oxygen would be the
electron donor) (Table 1 and Fig. 3).
Two hydrophobic moieties (C and D) are key components of the common pharmacophore (Fig. 5A). In
relation to the BoNT/A LC substrate binding cleft, C
and D correspond to binding subsites 1 and 2, and facilitate hydrophobic collapse between inhibitors and the
enzyme. The C ! D distance range of the common
pharmacophore shown in Fig. 5A reﬂects the extent of
the potential binding space that inhibitors may occupy
in subsite 2 of the BoNT/A LC substrate binding cleft.
Examples of C and D in inhibitors, as they map to the
common pharmacophore, include: the two methoxy
substituents of michellamine B (separated by a distance
) (Table 1 and Figs. 2 and 3); the two chlorines
of 8.6 A

of the BQs (separated by an average distance of 9.8 A
for all examined BQs) (Table 2 and Figs. 3, 4, and 5B);
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and the two dihydro imidazolyl moieties of NSC 357756
) (Table 1 and Fig. 3).
(separated by a distance of 15.8 A
The ﬁnal component (E) of the common pharmacophore is a positive ionizable substituent (Fig. 5A). While
inhibitor docking studies have shown that an ionizable
moiety may participate in electrostatic interactions with
enzyme residues, the positive charge may also aid in
solubilizing inhibitors bound within the BoNT/A LC
substrate binding cleft; unlike a traditional binding
pocket, the BoNT/A LC substrate binding cleft is large
and almost completely solvent exposed. Hence, it is
plausible that a hydrogen bonding network involving
the positively charged moiety(ies) of the inhibitors and
surrounding water molecules also serves to stabilize
compound binding. Examples of inhibitor components
that map to E include: the ionizable secondary nitrogen
in one of the michellamine B tetrahydroisoquinolines
(Table 1 and Figs. 2 and 3); the secondary nitrogens in
the ﬂexible linkers of BQs (Table 2 and Figs. 3, 4, and
5B); and the tertiary nitrogens in amodiaquine, chloroquine, and quinacrine (Table 2). Interestingly, the determined BoNT/A LC peptide cleavage site of the
natural substrate, SNAP-25, is between a glutamine and
an arginine [34]. Furthermore, the distance between the
side-chain guanidinum of arginine (which is ionized at
physiological pH) and the backbone Ca of this residue
corresponds to the distance between A and E in the
common pharmacophore. Hence, it is possible that the
ionizable substituent of the inhibitors may be mimicking
contacts made by the side-chain guanidinium of the indicated Arg residue of SNAP-25.

Summary
These experiments have, for the ﬁrst time, identiﬁed
small organic (non-peptidic) lead therapeutics that inhibit BoNT/A LC protease activity in the low lM range.
Based on the structures of these lead therapeutics, molecular modeling studies have been used to propose a
common pharmacophore. This pharmacophore will
serve as the basis for directing future database mining
studies and synthetic organic chemistry projects to
identify and develop BoNT/A LC inhibitors with enhanced potency.
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